Medtronic will also work with Canary Health to develop programs that enlist Medtronic’s devices, services and infrastructure and Canary Health’s behavior change programs, design, and user engagement insights.
“I think we’re going to hear more about SGLT2 inhibitors because they’re easy for patients to use and for physicians to prescribe,” said conference attendee Athena Philis-Tsimikas corporate vice president of the Scripps Whittier Diabetes Institute.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.